BSX241220C92500
- 0.55
- 0.000.00%
Boston Scientific Newsroom
Boston Scientific (BSX) Stock Moves -0.03%: What You Should Know
Morgan Stanley Maintains Boston Scientific(BSX.US) With Buy Rating, Maintains Target Price $100
Optimistic Outlook for Boston Scientific's Urology Segment Drives Buy Recommendation
FDA Roundup: December 17, 2024
JP Morgan Maintains Overweight on Boston Scientific, Raises Price Target to $110
FDA Alerting About Potential Need For Early Device Replacement Of Boston Scientific Accolade Pacemaker Devices; Boston Scientific Announced Recall For Subset Of Accolade Pacemaker Devices With Increased Risk To Permanently Enter Safety Mode
Goldman Sachs Raises Price Target on Boston Scientific to $103 From $102, Maintains Buy Rating
Investing in Boston Scientific (NYSE:BSX) Three Years Ago Would Have Delivered You a 121% Gain
Jim Cramer on Boston Scientific Corporation (BSX): 'A Superior Company'
Boston Scientific Is Maintained at Buy by TD Cowen
Innovations and Buyouts Support BSX Stock Amid Macroeconomic Woes
Market Mania Won't Last. Buy These 8 Stocks to Weather the Storm, Analyst Says.
TD Cowen Maintains Boston Scientific(BSX.US) With Buy Rating, Raises Target Price to $110
TD Cowen Adjusts Price Target on Boston Scientific to $110 From $100, Maintains Buy Rating
Boston Scientific (BSX) Ascends But Remains Behind Market: Some Facts to Note
Unusual Options Activity: CVS, BSX and Others Attract Market Bets, CVS V/OI Ratio Reaches 405.0
EST Dec 11th Closing Delivery - In the last three hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
Boston Scientific Is Maintained at Overweight by Wells Fargo
Express News | Boston Scientific Cmo Discuss Solutions for Health Inequality on Today's Marketplace
Boston Scientific CMO Discuss Solutions for Health Inequality on Today's Marketplace
Wells Fargo Maintains Boston Scientific(BSX.US) With Buy Rating, Raises Target Price to $100